Mylan CEO Heather Bresch told CNBC on Monday that the pharmaceutical company’s global supply chain experienced “minimal disruption” during the coronavirus pandemic.
“As Covid hit different areas of the world at different points in time, [being] able to navigate and leverage the different aspect of our supply chain, really allowed us to really have minimal disruption,” Bresch said on “Closing Bell.”
Bresch said Mylan has more than 40 facilities across the world, which allows the company to be “near patients that need the treatment.” Supply chain diversification over the last decade has been beneficial to Mylan, Bresch said.
The global nature of medical supply chains, and whether it could contribute to potential drug shortages, came into focus during the outbreak of Covid-19, which has infected 4.1 million people worldwide, according to Johns Hopkins University data. At least 285,000 people have died.
Trump administration officials such as White House trade advisor Peter…
